blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3546577

EP3546577 - CHEMICALLY-MODIFIED SIRNA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.09.2022
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  21.10.2021
FormerGrant of patent is intended
Status updated on  09.06.2021
FormerRequest for examination was made
Status updated on  30.08.2019
FormerThe international publication has been made
Status updated on  16.06.2018
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
NapaJen Pharma, Inc.
527, 533 Airport Boulevard
Burlingame, California 94010 / US
[2019/40]
Inventor(s)01 / HIGUCHI, Sadaharu
c/o NapaJen Pharma, Inc.
1204 University Research Administration Center
Tokyo University of Agriculture and Technology
2-24-16 Nakacho
Koganei-shi Tokyo 184-8588 / JP
02 / UNO, Atsushi
c/o NapaJen Pharma, Inc.
1204 University Research Administration Center
Tokyo University of Agriculture and Technology
2-24-16 Nakacho
Koganei-shi Tokyo 184-8588 / JP
03 / ANDO, Hironori
c/o NapaJen Pharma, Inc.
1204 University Research Administration Center
Tokyo University of Agriculture and Technology
2-24-16 Nakacho
Koganei-shi Tokyo 184-8588 / JP
 [2019/40]
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[2019/40]
Application number, filing date17872923.227.11.2017
[2019/40]
WO2017JP42439
Priority number, dateJP2016023064028.11.2016         Original published format: JP 2016230640
[2019/40]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018097296
Date:31.05.2018
Language:JA
[2018/22]
Type: A1 Application with search report 
No.:EP3546577
Date:02.10.2019
Language:EN
[2019/40]
Type: B1 Patent specification 
No.:EP3546577
Date:17.11.2021
Language:EN
[2021/46]
Search report(s)International search report - published on:JP31.05.2018
(Supplementary) European search report - dispatched on:EP29.05.2020
ClassificationIPC:C12N15/113
[2019/40]
CPC:
C12N15/113 (EP,KR,US); C12N2310/14 (EP,KR,US); C12N2310/315 (US);
C12N2310/344 (EP); C12N2310/351 (US); C12N2310/3519 (EP,KR);
C12N2320/32 (KR); C12N2320/51 (KR,US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP);
C12N2310/322, C12N2310/3533 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/40]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CHEMISCH MODIFIZIERTE SIRNA[2019/40]
English:CHEMICALLY-MODIFIED SIRNA[2019/40]
French:ARNSI CHIMIQUEMENT MODIFIÉ[2019/40]
Entry into regional phase22.05.2019Translation filed 
23.05.2019National basic fee paid 
23.05.2019Search fee paid 
23.05.2019Designation fee(s) paid 
23.05.2019Examination fee paid 
Examination procedure23.05.2019Examination requested  [2019/40]
21.12.2020Amendment by applicant (claims and/or description)
09.06.2021Communication of intention to grant the patent
05.10.2021Receipt of the translation of the claim(s)
07.10.2021Fee for grant paid
07.10.2021Fee for publishing/printing paid
Opposition(s)18.08.2022No opposition filed within time limit [2022/43]
Fees paidRenewal fee
19.11.2019Renewal fee patent year 03
16.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.11.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
MT17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
TR17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
[2026/04]
Former [2024/42]HU27.11.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
MT17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2024/23]HU27.11.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/33]HU27.11.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/30]AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/01]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/49]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/48]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/39]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/37]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/35]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
LU27.11.2021
BE30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/34]AT17.11.2021
EE17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
LU27.11.2021
BE30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/33]AT17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
BE30.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/25]AT17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/24]AT17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/23]AT17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
PL17.11.2021
RS17.11.2021
BG17.02.2022
PT17.03.2022
Former [2022/22]AT17.11.2021
FI17.11.2021
LT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/21]AT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/19]BG17.02.2022
Documents cited:Search[A] EP2865759  (JAPAN SCIENCE & TECH AGENCY et al.) [A] 1-3 * the whole document *
 [A] EP2226384  (NAT INST OF ADVANCED IND SCIEN et al.) [A] 1-3 * the whole document *
 [A] WO2005115481  (ALNYLAM PHARMACEUTICALS INC et al.) [A] 1-3 * claim 1; table 2 * * the whole document *
 [A] WO2005089224  (ALNYLAM PHARMACEUTICALS INC et al.) [A] 1-3 * figure 9; example 8; tables 4, 18 * * the whole document *
 [A] WO2016161374  (UNIV MASSACHUSETTS et al.) [A] 1-3 * figure 8 * * the whole document *
International search[A] WO2013021784  (NAPAJEN PHARMA INC et al.) [A] 1-3 * , claims 1-10 & US 2014/0294869 A1, claims 1-10 & EP 2742944 A1 *
 [A] WO2012020795  (NAPAJEN PHARMA INC et al.) [A] 1-3 * , claims 1-15 & US 2013/0142832 A1, claims 1-15 & EP 2682462 A1 *
 [A] WO2012117855  (NAPAJEN PHARMA INC et al.) [A] 1-3 * , claims 1-9 & US 2014/0128448 A1, claims 1-9 & EP 2682462 A1 *
 [A] WO2009078470  (NAT INST OF ADVANCED IND SCIEN et al.) [A] 1-3 * , claims 1-13 & US 2011/0111501 A1, claims 1-13 & EP 2226384 A1 & CN 101918554 A *
 [A] WO2016011306  (MODERNA THERAPEUTICS INC et al.) [A] 1-3 * , paragraphs [0744] - [0761] & JP 2017-523777 A & US 2017/0202979 A1 & EP 3169783 A2 *
 [A] WO2015101415  (CUREVAC GMBH et al.) [A] 1-3 * , pp. 56-58 & JP 2017-502669 A & US 2016/0304883 A1 & EP 3090052 A1 *
 [A] WO2015161276  (EDITAS MEDICINE INC et al.) [A] 1-3 * , pp. 352-354 & JP 2017-513485 A & US 2017/0175128 A1 & EP 3132030 A2 & KR 10-2017-0009865 A *
by applicantWO2009078470
   JESPER B. BRAMSENJORGEN KJEMS: "Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering", FRONT GENET, vol. 3, 2012, pages 54, XP055134928, DOI: doi:10.3389/fgene.2012.00154

DOI:   http://dx.doi.org/10.3389/fgene.2012.00154
   KARIN E. LUNDINOLOF GISSBERGC.I. EDVARD SMITH: "Oligonucleotide Therapies: The past and the Present", HUM GENE THER, vol. 26, no. 8, 1 August 2015 (2015-08-01), pages 475 - 485, XP055376603, DOI: doi:10.1089/hum.2015.070

DOI:   http://dx.doi.org/10.1089/hum.2015.070
   SHOWKAT AHMAD DARANAMIKA THAKURABID QURESHIMANOJ KUMAR: "siRNAmod: A database of experimentally validated chemically modified siRNAs", SCI REP, vol. 6, 2016, pages 20031
   GULNIHAL OZCANBULENT OZPOLATROBERT L. COLEMANANIL K. SOODGABRIEL LOPEZ-BERESTEIN: "Preclinical and clinical development of siRNA-based therapeutics", ADV DRUG DELIV REV, vol. 87, 29 June 2015 (2015-06-29), pages 108 - 119, XP055504648, DOI: doi:10.1016/j.addr.2015.01.007

DOI:   http://dx.doi.org/10.1016/j.addr.2015.01.007
   UI-TEI ET AL., NUCLEIC ACIDS RES., vol. 32, 2004, pages 936 - 948
   A.C.S., vol. 38, no. 1, 1997, pages 253
   CARBOHYDRATE RESEARCH, vol. 89, 1981, pages 121 - 135
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.